Compare Mesoblast Limited (MESO) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Upstart Holdings Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Upstart Holdings Inc trades at $29.6 (market cap $2.76B). The key difference: Upstart Holdings Inc is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MESO | UPST | |
|---|---|---|
Market Cap | $2.17B | $2.76B |
Sector | Technology | Financials |
52-Week High | $20.96 | $84.13 |
52-Week Low | $12.88 | $24.22 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Upstart Holdings trades at $28.68, down 2.81% on the day, with a bearish technical signal but oversold RSI levels. The company reported a net income of $53.60M in 2025, a significant improvement from prior losses, though recent Q1 2026 earnings missed expectations. Revenue growth to $1.02B in 2025 and expanding AI lending platform into auto and home loans highlight operational progress.
The stock presents a recovery opportunity with analyst consensus target of $42.00, but faces risks from volatile earnings, high debt levels, and margin pressure. Investor sentiment is mixed amid ongoing execution challenges in a competitive fintech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
